Literature DB >> 9115286

Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium/iron uptake, increased activity of iron regulatory protein-1, and decreased ferritin production.

C R Chitambar1, J P Wereley.   

Abstract

The mechanism of drug resistance to gallium nitrate is not known. Since gallium can be incorporated into ferritin, an iron storage protein that protects cells from iron toxicity, we investigated whether ferritin expression was altered in gallium-resistant (R) CCRF-CEM cells. We found that the ferritin content of R cells was decreased, while heavy chain ferritin mRNA levels and iron regulatory protein-1 (IRP-1) RNA binding activity were increased. IRP-1 protein levels were similar in gallium-sensitive (S) and R cells, indicating that R cells contain a greater proportion of IRP-1 in a high affinity mRNA binding state. 59Fe uptake and transferrin receptor expression were decreased in R cells. In both S and R cells, gallium inhibited cellular 59Fe uptake, increased ferritin mRNA and protein, and decreased IRP-1 binding activity. Gallium uptake by R cells was markedly diminished; however, the sensitivity of R cells to gallium could be restored by increasing their uptake of gallium with excess transferrin. Our results suggest that R cells have developed resistance to gallium by down-regulating their uptake of gallium. In parallel, iron uptake by R cells is also decreased, leading to changes in iron homeostasis. Furthermore, since gallium has divergent effects on iron uptake and ferritin synthesis, its action may also include a direct effect on ferritin mRNA induction and IRP-1 activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9115286     DOI: 10.1074/jbc.272.18.12151

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Cellular adaptation to down-regulated iron transport into lymphoid leukaemic cells: effects on the expression of the gene for ribonucleotide reductase.

Authors:  C R Chitambar; J P Wereley; T Heiman; W E Antholine; W J O'brien
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

Review 2.  Gallium-containing anticancer compounds.

Authors:  Christopher R Chitambar
Journal:  Future Med Chem       Date:  2012-06       Impact factor: 3.808

3.  Biological study of the effect of water soluble [N-(2-hydroxybenzyl)-L-aspartato] gallium complexes on breast carcinoma and fibrosarcoma cells.

Authors:  Ahmed Mohsen; Charles Saby; Philippe Collery; Gilane Mohamed Sabry; Rasha Elsherif Hassan; Abdelfattah Badawi; Pierre Jeannesson; Didier Desmaële; Hamid Morjani
Journal:  J Biol Inorg Chem       Date:  2016-08-02       Impact factor: 3.358

Review 4.  Medical applications and toxicities of gallium compounds.

Authors:  Christopher R Chitambar
Journal:  Int J Environ Res Public Health       Date:  2010-05-10       Impact factor: 3.390

5.  (E)-N'-{7-Meth-oxy-spiro-[chromeno[4,3-d]thia-zole-4,1'-cyclo-hexa-n]-2-yl}-N,N-dimethyl-acetimidamide.

Authors:  Kamini Kapoor; Vivek K Gupta; Rajni Kant; Poorvesh M Vyas; Mihir J Joshi; Kalpesh M Menpara; Kartik D Ladva
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-10-05

6.  1-(5-Bromo-4-phenyl-1,3-thia-zol-2-yl)pyrrolidin-2-one.

Authors:  Hazem A Ghabbour; Adnan A Kadi; Hussein I El-Subbagh; Tze Shyang Chia; Hoong-Kun Fun
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-05-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.